TB Drug Discovery
UP-PMI, together with the Unite de Biochimie Structurale ( directed by Pr. Pedro Alzari) are consortium partners in the FP6 integrated program
"NM4TB" New Medicins for Tuberculosis
NM4TB aims to discover and develop new drugs for the treatment of TB through an integrated approach implemented by a team, that combines some of Europe's leading academic TB researchers, with a major pharmaceutical company and a SME, all with a strong commitment to discovering new anti-infective agents. NM4TB has a comprehensive portfolio of potential and validated targets plus several novel, proprietary anti-TB agents in its pipeline. For more details consult the NM4TB website (http://www.nm4tb.org).
Website Copyright © 2000-2009 by the Institut Pasteur.
All rights reserved
DISCLAIMER
The information contained in this webpage is provided in good faith, but no
warranty, nor any legal liability or responsibility for any purpose for
which the data are used, is given.
